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ABSTRACT
Palliative and end of life care is changing, becoming more widespread and improving for 
patients. Yet, the current literature in the field suggests that the evidence for palliative and end 
of life care is somewhat limited. Research on treatment decisions, family care, and advance 
directions are just a few of the areas that need rigorous research efforts. Palliative care research 
is essential in order to continue providing effective treatments to those suffering in the last 
stages of life. Indeed, the goal of good palliative care research is to relieve suffering and to 
improve quality of life. Similar to any other field, palliative care programs must develop on 
a research base, and patient care will suffer if it is not backed by sound research. However, 
weighted against this need are some who maintain that the ethical and practical challenges 
of palliative care research are unique and insurmountable. This analysis considers if distinct 
ethical guidelines are needed for palliative care research.
Keywords: palliative care; palliative sedation; vulnerability; end-of-life care; risk-benefit 
analysis; decision-making capacity.
Introduction
Palliative and end of life care is changing in many parts of the world, becoming more 
widespread and improving for patients. The current literature in the field of palliative 
medicine suggests that the evidence for palliative and end of life care is limited.1 
The American Academy of Hospice and Palliative Medicine released a statement 
1  Marcia Grant, Ronit Elk, Betty Ferrell, R. Sean Morrison, and Charles F. von Gunten, “Current Status of 
Palliative Care—Clinical Implementation, Education, and Research,” CA: A Cancer Journal for Clinicians, 59 
(2009), 332.
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in late 2014 emphasizing that many palliative care decisions and interventions lack 
sufficient evidence to either recommend or not recommend.2 Research on treatment 
decisions, family care, and advance directions are just a few of the areas that need 
rigorous research efforts. Resources for such research, although limited, have begun 
to fund needed studies.3 Palliative care research is essential in order to continue 
providing effective treatments to those suffering in the last stages of life. Indeed, the 
goal of good palliative care research is to relieve suffering and to improve quality of 
life.4 Similar to any other field, palliative care programs must develop on a research 
base, and patient care will suffer if it is not backed by sound research.5 However, 
weighted against this need are some who maintain that the ethical and practical 
challenges of palliative care research are unique and insurmountable.6 
While we must not take lightly the fact that palliative care researchers confront an 
array of ethical dilemmas, does the distinctiveness of palliative care research require 
distinct ethical guidelines? That is, do the ethical issues that arise in palliative care 
research extend beyond those of standard research trials? Thus, at the heart of this 
debate is the question of whether palliative care research creates new or unique 
ethical challenges. The answer to this question will have significant implications for 
the design and conduct of palliative care research.7 
This analysis will consider three arguments that may be raised to support the claim 
that palliative care research raises distinct ethical issues. The three arguments that 
will be considered are that: 1) Palliative care patients are especially vulnerable; 
2) Research investigators must obtain consent from patients and families; and 
3) The risks and benefits of palliative research are difficult to assess. These three 
arguments are considered here because the literature suggests they are the issues 
that are most disturbing to investigators, healthcare providers, and the public.8 
All three of the arguments outlined above may create considerable challenges for 
palliative care investigators. Nonetheless, the central thesis of this analysis is that the 
2  American Academy of Hospice and Palliative Medicine, Statement on Palliative Care Research, November 
2014: http://aahpm.org/positions/research-ethics
3  Grant, et. al., “Current Status of Palliative Care—Clinical Implementation, Education, and Research,” 332.
4  David Casarett, “Ethical Issues in Palliative Care Research,” in Oxford Textbook of Palliative Medicine, 4th 
edition, edited by Geoffrey Hanks, Nathan Cherny, Nicholas Christakis, Marie Fallon, Stein Kaasa, and Russell 
Portenoy, 416-21, (New York: Oxford University Press, 2011) 416.
5  Neil MacDonald and Charles Weijer, “Ethical Issues in Palliative Care Research,” in Oxford Textbook of 
Palliative Medicine, 3rd edition, edited by Derek Doyle, Geoffrey Hanks, Nathan Cherny and Kenneth Calman, 
76-83. (New York: Oxford University Press, 2004), 77.
6  A.M. Jubb, “Palliative Care Research: Trading Ethics for an Evidence Base,” Journal of Medical Ethics 28, no. 
6 (2002): 342.
7  David J. Casarett and Jason H.T. Karlawish, “Are Special Ethical Guidelines Needed for Palliative Care 
Research?” Journal of Pain and Symptom Management 20, no. 2 (2000): 130-31.
8  Casarett and Karlawish, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 131.
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issues of vulnerability and informed consent do not merit requiring distinct ethical 
guidelines. However, there does appear to be distinct ethical challenges in analyzing 
risks and benefits in palliative care research, though it does appear these challenges 
are surmountable. This analysis will proceed by initially providing an overview of 
the research process and its relation to palliative care. It will then analyze the human 
rights concerns of vulnerability and informed consent that come into focus when 
conducting research on palliative care patients. An examination of the argument that 
assessing risks and benefits in palliative care research is difficult, which is somewhat 
distinct to this field, follows. Lastly, further considerations to protect research 
participants, including the ideas of compassion and vigilance, are brought forward.
Research Ethics
The development of contemporary research ethics has been quite difficult. From 
a historical perspective, paternalism has held a prominent place in healthcare for 
the majority of its past. Further, the crimes against humanity committed by the 
Nazi regime under the guise of human research, and more recent offenses such as 
the Tuskegee syphilis experiments that were not concluded until 1972, still resound 
clearly in the field of research ethics. It is against this challenging background that 
research ethics evolved.9 This section considers the research process and its application 
to palliative care.
The Research Process and Palliative Care
Clinical trials provide the strongest evidence for the effectiveness, efficiency, 
and acceptability of clinical interventions. Without evidence from clinical trials, 
clinicians lack an important source of information to guide their practice. This may 
be a particular issue in palliative medicine where clinical research has not evolved at 
the same pace as palliative care programs. The result of this has been limited evidence 
for many of the interventions used in palliative care. Indeed, many pharmacological 
interventions that are in common use in palliative care have not been robustly 
tested in broad clinical trials.10 Yet, as in any other healthcare field, clinicians have 
9  Franz-Josef Illhardt and Henk ten Have, “Research Ethics in Palliative Care,” In The Ethics of Palliative Care: 
European Perspectives, edited by Henk ten Have and David Clark, 198-211, (Buckingham, England: Open 
University Press, 2002), 202.
10  Yolanda Zuriarrain Reyna, Michael I. Bennett, and Eduardo Bruera, “Ethical and Practical Issues in Designing 
and Conducting Clinical Trials in Palliative Care,” in Research Methods in Palliative Care, edited by Julia M. 
Addington-Hall, Eduardo Bruera, Irene J Higginson, and Sheila Payne, 27-41, (New York: Oxford University 
Press, 2007), 27.
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an obligation to provide the best possible treatment and care to patients at the end 
of their lives. The only way to ensure that high medical standards are established 
and maintained is through an understanding of the pathophysiological processes in 
patients with advanced disease and by evaluating the treatments that are employed 
using the most robust methodology possible.11 Therefore, if palliative care patients 
are to receive the best imaginable care, an appropriate evidence base that is grounded 
in clinical research must be furthered. Hence, clinical trials are a key part of good 
clinical practice, even in the palliative care setting.12
The first question that palliative care investigators face in designing an ethical research 
study is whether it is research or quality improvement (QI). This decision is very 
significant and has profound implications for both the study’s design and the ethical 
standards to which it will be held. For example, US federal law requires research 
projects be approved by local IRBs to ensure that informed consent is obtained 
from each subject, that research risks are reasonable in relation to expected benefits, 
and that subjects are recruited in an equitable fashion. In comparison, there are few 
widely accepted standards that govern QI. In many situations this delineation is 
clear. However, QI activities often share many of the characteristics of research. For 
instance, both QI and research involve systematic data collection methods, both may 
apply statistical methods to test hypotheses, establish relationships among variables, 
and evaluate outcomes, and both are designed to produce knowledge that could 
benefit patients other than those directly involved in the activity. Therefore, QI and 
research activities can at times be difficult to distinguish, and may be particularly 
difficult in end-of-life research. This may result in confusion and conflicting opinions 
from IRBs that review study protocols.13 
The research process in the healthcare setting unfolds within a series of particular 
stages. The basic idea and hypothesis must first be elaborated. Despite having a 
clear hypothesis about the outcome of the trial, it is essential that this is merely an 
assumption and the investigator does not have evidence or an overwhelming belief 
to the contrary. Indeed, there is a consensus that at the beginning of a trial that 
compares two or more treatments, an honest null hypothesis must exist.14 This state 
of not knowing the outcome is called “equipoise,” and it is an essential component 
11  Geoffrey Hanks, Stein Kaasa, and Karen Forbes, “Research in Palliative Care,” in Oxford Textbook of Palliative 
Medicine, 4th edition, edited by Geoffrey Hanks, Nathan Cherny, Nicholas Christakis, Marie Fallon, Stein Kaasa, 
and Russell Portenoy, 361-74 (New York: Oxford University Press, 2011): 362.
12  Reyna, et. al., “Ethical and Practical Issues in Designing and Conducting Clinical Trials in Palliative Care,” 27.
13  David Casarett, “Ethical Considerations in End-of-Life Care and Research,” Journal of Palliative Medicine 8, 
no. supplement 1 (2005), S149.
14  MacDonald and Weijer, “Ethical Issues in Palliative Care Research,” 80.
Daniel J. Hurst: Does the Distinctiveness of Palliative Care Research Require Distinct Ethical Guidelines?  pp. 31–57
35
of ethical research.15 Once a research goal has been identified, it is then necessary to 
work out how to achieve it in a reliable way.16 This is followed by the design of the 
methodological procedure and creating the research study protocol. An ethics review 
board must then approve the research protocol. The purpose of these reviews is to 
safeguard the rights and welfare of human research subjects. They examine risks to 
human subjects, ensure that consent is properly attained, and certify that the overall 
design of the study is scientifically sound.17 Once the protocol has been approved it 
may then be carried out. The results of the study, which may take a significant amount 
of time to collect, will be analyzed. New medical interventions and treatments may 
be developed on the basis of what is learned by the study.18 Palliative research does 
present unique issues over other forms of medical research. The end result of palliative 
care is always the same: a deceased patient, and family and friends that are left in 
mourning. In palliative research, it is unlikely that the patient and his family would 
experience any benefit from presumed new interventions as patient’s lifespan is very 
limited, and this perspective should be described in detail in the research design. For 
healthcare providers, one of the hardest questions in palliative medicine is how to tell 
the truth but leave room for hope. 
Research in healthcare is distinguished from research in other areas because it has 
a particular objective and because it typically involves the participation of human 
subjects. The objective of research in healthcare is focused on finding novel or better 
methods of treatment. To achieve this aim, there must be a continual effort within 
the healthcare sector to generate new data that can be applied to the medical care of 
patients who are suffering due to limited treatment options and a deficiency of medical 
knowledge. Thus, new studies must be constantly initiated in order to improve the 
current standards of treatment and better patient care. Further, the participation of 
human subjects is a distinguishing mark of medical research. Prior to clinical research 
on humans, animal experiments are performed and their results are analyzed and the 
drug or new therapy must be approved for clinical trials in human subjects.19  
As this analysis shifts to palliative care research in particular, it is important to clarify 
what is meant by the term. The World Health Organization defines palliative care as 
“an approach that improves the quality of life of patients and their families facing the 
15  Michael I. Bennett, “Principles of Designing Clinical Trials in Palliative Care,” in Research Methods in Palliative 
Care, edited by Julia M. Addington-Hall, Eduardo Bruera, Irene J Higginson, and Sheila Payne, 13-26, (New York: 
Oxford University Press, 2007), 14.
16  Claire Foster, The Ethics of Medical Research on Humans, (New York: Cambridge University Press, 2001), 21. 
17  U.S. Food and Drug Administration. “Institutional Review Boards Frequently Asked Questions – Information 
Sheet.” http://www.fda.gov/RegulatoryInformation/Guidances/ucm126420.htm
18  Illhardt and ten Have, “Research Ethics in Palliative Care,” 200.
19  Illhardt and ten Have, “Research Ethics in Palliative Care,” 200-01.
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problem associated with life-threatening illness, through the prevention and relief of 
suffering by means of early identification and impeccable assessment and treatment 
of pain and other problems, physical, psychosocial and spiritual”.20 This article is 
particularly concerned with the physical aspect of palliative care and its research. 
The benefits of palliative care research to future patients seem fairly obvious, for if 
palliative care research is designed to produce knowledge that will advance end of life 
care, then implicit in this goal is the expectation that this knowledge will improve 
care for future patients. These benefits to future patients may be described in terms 
of the study’s validity and value. Palliative care researchers must use methods in their 
research that can be agreed upon by peer reviewers; thus, their study methods must 
be valid. All studies must further be designed in such a way as to produce knowledge 
that is generalizable. That is, the research findings need to be able to be extended to 
the population at large. Validity is a threshold requirement for all research, because, 
as it has been recognized, it is unethical to expose participants to research risks that 
peer reviewers agree cannot answer a research question.21 
Moreover, the study’s value must be taken into account. As defined broadly, value 
can be taken as the likelihood that the study’s results will improve the health and 
wellbeing of future patients. Validity is an important measure of both a study’s 
scientific and ethical quality. One reason why patients participate in research is to 
generate knowledge that will benefit those patients who come after them. Because 
subjects are willing to accept risks and burdens of research in order to benefit future 
patients, investigators have an ethical responsibility to maximize the possibility that 
a research study will do so.22 However, it must also be considered whether there are 
benefits to those who participate in research, which will be examined in section 4 of 
this analysis. 
Nonetheless, some commentators, such as Jeanne Quint Benoliel, suggest that there 
is merit in raising the general question as to whether dying patients should ever 
properly be subjects for scientific study.23 Similarly, Munhall argues that all research 
turns people into mere means, regardless of whether or not the research participant 
is expected to benefit from the experience.24 Additionally, Louise de Raeve has 
supported the argument that strong moral grounds exist for objecting to research in 
20  http://www.who.int/cancer/palliative/definition/en/
21  Casarett, “Ethical Issues in Palliative Care Research,” in Oxford Textbook of Palliative Medicine, 416.
22  Casarett, “Ethical Issues in Palliative Care Research,” in Oxford Textbook of Palliative Medicine, 416.
23  Jeanne Quint Benoliel, “Research with Dying Patients,” in Patients, Nurses, Ethics, edited by A. J. Davis, J. C. 
Krueger (New York: American Journal of Nursing, 1980): 119-28. 
24  P. L. Munhall, “Ethical Considerations in Qualitative Research,” Western Journal of Nursing Research 10, no. 
2 (1988), 150-56. 
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palliative care. De Raeve argues from both a Kantian and risk-benefit perspective.25 
While the Kantian argument will not be addressed in this analysis, the question of 
risk-benefit will be examined at length. At this juncture it should be noted that it 
is currently generally accepted that, whatever the sensitivities around palliative care 
research, in the long run palliative care patients will be disadvantaged if there is a 
lack of evidence to support improvements and initiatives in palliative care. Therefore, 
though palliative care research poses many challenges from an ethical point of view, 
this should not discourage researchers from undertaking research in this field. The 
remainder of this analysis will consider these ethical issues.26
Universal Human Rights Considerations
Numerous ethical concerns are present in palliative care research, which should not 
be diminished. Indeed, there have been concerns raised from several commentators 
about whether it is ever appropriate to allow patients near the end of life to participate 
in research.27 These arguments have considerable intuitive appeal and must be 
seriously addressed.28 However, it must also be understood that overly strict limits 
on palliative research can also cause harm by impeding the establishment of new 
knowledge that will improve future patient care. 
In order to be valid, arguments against research in a palliative setting must demonstrate 
that dying patients constitute a special class of research subjects, for whom research 
raises distinct ethical challenges that are insurmountable. From this stance, one may 
argue that special, distinct restrictions, protection, and guidelines are necessary to 
direct research. In contrast, if patients near the end of life are not subject to unique 
ethical constraints, then research may be acceptable within the context of strategies 
devised to protect subjects who pose similar challenges.29 This section examines 
the two major human rights considerations in the context of research ethics, and 
specifically, palliative care research: vulnerability and informed consent.
Vulnerability
One reason to consider special ethical guidelines for palliative care patients is that 
they may be considered a vulnerable population. Surely palliative care patients are 
25  Louise de Raeve, “Ethical Issues in Palliative Care Research,” Palliative Medicine 8, no.4 (1994), 298-305.
26  Scottish Partnership for Palliative Care, A Beginner’s Guide to Successful Palliative Care Research, (Edinburgh: 
Scottish Partnership for Palliative Care, 2011), 17.
27  de Raeve, “Ethical Issues in Palliative Care Research,” 298-305.
28  David Casarett, “Ethical Issues in Palliative Care Research,” in Oxford Textbook of Palliative Medicine, 416.
29  Jubb, “Palliative Care Research: Trading Ethics for an Evidence Base,” 343.
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not a homogenous group, yet they are a group for whom there is often no second 
opportunity to improve care.30 Due to disease processes and the effects of palliative 
medicines there also may be some degree of decisional impairment. The Institutional 
Review Board Guidebook developed by the Department of Health and Human 
Services lists terminally ill patients as a special class of subjects, along with children, 
prisoners, and the mentally handicapped.31 A simplistic definition of vulnerability is 
that, it describes a group of subjects who may be relatively or absolutely incapable 
of protecting their own interests.32 The UNESCO Universal Declaration on Bioethics 
and Human Rights has provided an expanded definition of vulnerability. Article 8 
asserts that when applying scientific knowledge and medical practice to individuals, 
the vulnerability of men and women must be taken into account. That is, individuals 
and groups of distinct vulnerability should be protected and respected. UNESCO 
defined vulnerability broadly as the susceptibility of being wounded.33 
The notion of human vulnerability should not merely be applied to individuals in 
lower income lands. It is now widely accepted that vulnerability is universal in scope. 
That is, at some time in life, all humankind is vulnerable, regardless of social status, 
intelligence, authority, or economic power.34 For many, the state of vulnerability 
is transient or contextual rather than inherent. However, it is to those individuals, 
groups, or communities for whom vulnerability is not a transient state that attention 
is particularly important.35 For example, by definition, being a terminal patient is 
not a transient state, until death occurs. To be certain, the notion of vulnerability is 
a criticism of the conventional emphasis on individual autonomy as insufficient, and 
that attention should be directed towards the conditions for humanity’s flourishing.36 
What is more, the principle of respect for human vulnerability should be linked to 
that of human dignity, which reinforces the notion of the unconditioned value of 
humankind by demanding their inviolability.37
Palliative care patients may encounter vulnerability because they lack decision-
making capacity or because their choices are not truly voluntary. Decision-making 
capacity describes the ability of a person to understand given information and make 
30  Reyna, et. al., “Ethical and Practical Issues in Designing and Conducting Clinical Trials in Palliative Care,” 28.
31  U.S. Department of Health and Human Services, “Institutional Review Board Guidebook, Chapter VI, 
Special Classes of Subjects,” http://www.hhs.gov/ohrp/archive/irb/irb_chapter6.htm
32  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?”, 131.
33  H. ten Have, Michèle Jean, The UNESCO Universal Declaration on Bioethics and Human Rights, 155-64.
34  ten Have and Jean, The UNESCO Universal Declaration on Bioethics and Human Rights, 158.
35  Sheila .A.M. McLean, “Respect for Human Vulnerability and Personal Integrity,” in Handbook of Global 
Bioethics, edited by Henk ten Have and Bert Gordijn (New York: Springer, 2013), 108.
36  Henk ten Have, “Vulnerability as the Antidote to Neoliberalism in Bioethics.” Revista Redbioetica 2014; 1 
(9): 87-92.
37  ten Have and Jean, The UNESCO Universal Declaration on Bioethics and Human Rights, 161-62.
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a cogent choice. The concern is that this capacity may be impaired in patients near 
the end of life, which is based largely on observations that terminal patients regularly 
have evidence of cognitive impairment. To be sure, this has the ability of leading 
to impaired decision-making capacity and inadequate informed consent. Though 
not all patients with cognitive impairment will lack decision-making capacity, 
informed consent for these patients will be more difficult or impossible. Since 
cognitive impairment appears to be quite common in this population, palliative care 
researchers may often have difficulty identifying those patients who lack decision-
making capacity and cannot provide consent.38
It must be recognized that this is a real challenge; however, the challenge is not unique 
to palliative care research. Hence, because it is not unique to palliative care research, 
it does not appear to provide grounds for distinct ethical guidelines. Investigators 
working in fields of research involving patients with dementia, psychiatric illness, 
and similar settings have developed strategies for assessing the decision-making 
capacity of such patients. Guidelines such as those provided by the National 
Bioethics Advisory Committee (NBAC) can be applied to palliative care research 
studies. The NBAC recommends that capacity should be assessed formally whenever 
research subjects are likely to be cognitively impaired and the research poses greater 
than minimal risk. Risks are determined to be greater than minimal if they are 
greater than those encountered in everyday life, or routine medical care. Indeed, as 
research risks increase and the chance of benefit decreases, decision-making capacity 
becomes increasingly essential. For instance, in high risk, low benefit research, to 
incorrectly assume that a patient is competent would be a grim mistake. This strategy 
is reasonable in palliative care research because the risks to which subjects are exposed 
are highly variable. While some studies involve only questionnaires or surveys, others 
involve experimental medications or risky procedures. When palliative care research 
involves only minimal risks, such as those posed by questionnaires, formal capacity 
assessments may not always be required. However, capacity assessment is more 
significant for studies that carry greater risks, such as those that involve a placebo 
when an effective agent is available, or an invasive intervention.39
Voluntariness is a second concern about vulnerability that must be considered. 
The voluntariness of a subject to consent to research participation has been at the 
forefront of research ethics since the Nuremberg Trials. In general terms, a choice 
is said to be voluntary if it is made without significant controlling influences.40 
The issue with palliative care research is that a subject’s choice to participate may 
38  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 131.
39  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 131-32.
40  Casarett, “Ethical Issues in Palliative Care Research,” in Oxford Textbook of Palliative Medicine, 419-20.
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be limited if their suffering has created a sense of desperation. If this concern is 
legitimate, voluntary consent in palliative care research may be confounded by the 
uncontrollable symptoms that are common in patients near the end of life.41 What is 
more, a patient may feel some compulsion or obligation to participate in a research 
study, especially if they rely on a research institution or investigator for their care. This 
influence may be powerful in a palliative care setting and constitute some manner of 
involuntariness on the part of the patient.42 
Though it is reasonable to suspect that these influences exist in palliative care settings, 
it is not at all clear that they present more of a danger than they do in other fields 
of human research. As has been recognized in the prevailing literature, a sense of 
desperation is not unique to palliative care patients. Oncology patients may feel 
a similar manner of desperation that influences their decision to enroll in phase I 
oncology clinical trials, even though the likelihood of attaining a medical benefit 
is remote. Therefore, it does not appear that these risks are unique to palliative 
care research. Further, the principle of respect for patient autonomy supports the 
potential involvement of patients in research that may not be of immediate benefit 
to themselves.43 The voluntariness of a participant can be protected by ensuring that 
a participant’s decision to enroll in a study is made with full knowledge of available 
alternatives and with the knowledge that he or she may withdraw at any time without 
penalty.44 This is required by US law and the regulations of many other states, though 
it may not be emphasized sufficiently. Even more, palliative care researchers may find 
it beneficial to recruit participants through a third party. This serves to underscore 
the distinction made between research and clinical care, and may clarify to patients 
that they can decline participation without jeopardizing their clinical care.45
Informed Consent 
A second reason to support the claim that palliative care research raises unique 
ethical issues is that investigators must obtain consent from patients. The notion 
of informed consent, similar to voluntariness, has been near the forefront of the 
concerns of medical ethics since at least the Nuremberg Trials in 1945-46. Informed 
consent refers to an individual’s autonomous authorization of a medical procedure or 
of involvement in research. This involves more than a simple agreement or complying 
41  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 132.
42  Russell Portenoy and Mitchell Max, “Pain Research—The Design of clinical trials,” in The Oxford Textbook 
of Clinical Medicine, 3rd edition, edited by Derek Doyle, Geoffrey Hanks, Nathan Cherny and Kenneth Calman, 
144-53, (New York: Oxford University Press, 2004), 143.
43  MacDonald and Weijer, “Ethical Issues in Palliative Care Research,” 80.
44  Casarett, “Ethical Issues in Palliative Care Research,” in Oxford Textbook of Palliative Medicine, 419-20.
45  Casarett and Karlawish, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 132.
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with a proposed medical intervention, for informed consent is a process, not a 
document. Explicit authorization of a medical intervention or research involvement 
through an act of informed and voluntary consent is essential. This can occur only 
if the patient or human research subject has gained substantial understanding of the 
proposed action and are void of substantial control by others.46 
Even after the establishment of the Nuremberg Code, it has been shown that certain 
medical experiments in the US were conducted without the informed consent 
of patients. Examples of this abound and include the Willowbrook State School 
experiments in Staten Island of the 1950s and 1960s47, as well as open-air tests of 
biological weapons over the US cities from 1949 to 1969 which resulted in the death 
of a man from San Francisco.48 Subsequently, the principle of informed consent was 
incorporated into the Declaration of Helsinki, and the World Medical Association 
proposed the need for ethics review committees to evaluate and control medical 
research. Thus, the Declaration of Helsinki was revised in 1975, in part, to urge 
the scientific community to look to ethics review committees for guidance prior to 
beginning a research project.49  
Palliative care researchers may face a number of challenges in the area of informed 
consent, however, none of these challenges are unique to palliative care.50 Some have 
attempted to argue that informed consent in palliative care research is problematic 
because the stability and duration of consent are uncertain.51 Patients nearing the end 
of life may lack decisional capacity or may experience fluctuating and/or declining 
capacity.52 The issue of whether patients are competent to give informed consent is 
one that needs to be taken seriously by all palliative care researchers.53 The dying 
person’s freedom to choose their own course of treatment should be protected as 
long as they are competent to decide such matters. Several commentators have 
noted that the medical profession itself may complicate this. The weaker and more 
ill a patient becomes, the more they will require the assistance of a caregiver. The 
46  Tom L. Beauchamp and James F. Childress, Principles of Biomedical Ethics, 7th ed. (New York: Oxford 
University Press, 2013), 120-25.
47  Frederick Adolf Paola, Robert Walker, Lois Lacivita Nixon, ed.. Medical Ethics and Humanities, (Sudbury, 
MA: Jones & Bartlett Publishers, 2009), 185–186.
48  Jonathan D. Moreno, Undue Risk: Secret State Experiments on Humans, (New York: Routledge, 2001) 233-34.
49  Illhardt and ten Have, “Research Ethics in Palliative Care,” 202.
50  Meera Agar, Danielle N. Ko, Caitlin Sheehan, Michael Chapman, and David C. Currow, “Informed Consent 
in Palliative Care Clinical Trials: Challenging but Possible,” Journal of Palliative Medicine 16, no. 5 (2013), 485. 
51  MacDonald and Weijer, “Ethical Issues in Palliative Care Research,” 79.
52  Susan Hickman, Juliana C. Cartwright, Christine A. Nelson, and Kathleen Knafl, “Compassion and Vigilance: 
Investigators’ Strategies To Manage Ethical Concerns in Palliative and End-of-Life Research,” Journal of Palliative 
Medicine 15, no. 8 (2012): 882.
53  Reyna, et. al., “Principles of Designing Clinical Trials in Palliative Care,” 31-33.
JAHR  Vol. 8/1  No. 15  2017
42
medical profession tends to create a paternalistic attitude in such circumstances. 
For irreversibly ill patients, treatment generally involves both the compensation 
for lost functions and the mobilization of remaining functions. Hence, while some 
paternalistic intervention may be necessary, many patients retain the freedom to 
choose and act, though this range may become increasingly restricted as the illness 
progresses. Although personal autonomy may gradually diminish, patients will rarely 
lose freedom completely. Hence, medical research in the field of palliative care should 
acknowledge the freedom of a patient, and the research ought to be compatible with 
it, otherwise it ought not to be done.54 
Furthermore, obtaining informed consent for palliative care research may be 
particularly delicate because participants may find it difficult to make such decisions 
at such a distressing point in their lives. Deciding how to describe the research trial 
also presents challenges, for certainly not all patients and families will have had full 
and open conversations with the physician about the patient’s current condition and 
prognosis. Another complication and reason why it has been suggested that palliative 
care research deserves distinct ethical guidelines is that investigators must often 
obtain consent not simply from patients, but also from families. Including families 
as subjects in the clinical research is a logical extension of hospice and palliative 
care, for the aim is often to provide family-centered care. Studies have explored not 
only new drugs or therapies on the patient, but also include issues such as family 
functioning, family perceptions, and the effect of the patient’s illness on the family. 
Indeed, there is reason to believe that families may become increasingly involved in 
palliative care research studies in the coming years. The Institute of Medicine and the 
National Institutes of Health have each called for more research on the experience of 
the families in distress.55 
In these types of studies, both the patient and the family are “subjects” because 
they are the focus of the research. These studies may create complex administrative 
challenges because of the need for investigators to generate an effective informed 
consent process tailored to meet the difficult needs of both patients and families. 
It is important to note, though, that these are administrative challenges created by 
the ethical obligation to obtain informed consent, and are not created by palliative 
care research itself. Indeed, investigators may look to the field of dementia research 
for some solutions. In dementia research studies, investigators often obtain a “dual 
consent”. That is, investigators obtain informed consent from both patients and 
family members simultaneously. This dual consent has the ability of assuring that 
family members understand the research and what is required of them to fulfill their 
54  Illhardt and ten Have, “Research Ethics in Palliative Care,” 202-03.
55  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 133.
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responsibilities. In dementia research, as in palliative care research, the responsibilities 
of the family or caregiver can be substantial, including transportation to the study 
site, giving medications, and assessment participation.56
Thus, though the informed consent process in palliative care research may be 
challenging, overcoming these difficulties is possible. Each clinical trial in palliative 
care must carefully develop an appropriate protocol to solve the specific problems 
the trial will bring.57 What is more, although research that includes multiple subjects 
does pose a real challenge for palliative care investigators, these are administrative 
challenges rather than purely ethical challenges. The situation of dementia research 
shows that the informed consent process in palliative care research is not unique in its 
complexity. Hence, palliative care researchers may learn from other fields of research, 
such as dementia research, the strategies to obtain consent from multiple subjects.58 
In summary, though issues of vulnerability, voluntariness, and informed consent may 
present ethical challenges to research in the palliative care milieu, it does not appear 
that they raise distinct challenges that merit distinct ethical guidelines. Though 
none of these challenges is unique to palliative care research, the combination and 
frequency with which they are encountered does require systematic and considered 
solutions.59 Thus, while these issues must not be taken lightly, it appears that the 
principles of research ethics are sufficient to protect human research participants 
from harmful practices.60 
Distinct Research Considerations for Palliative Care
Above has been presented that issues of vulnerability and informed consent, though 
raising significant challenges for IRBs and investigators, are not unique to palliative 
care research. Further, there seems to be manners of overcoming these challenges. 
Therefore, neither issues of vulnerability nor informed consent appear to justify 
special restrictions, protections, or guidelines, as the principles of research ethics can 
protect patients. However, this section examines the question of risk-benefit analysis, 
which may provide such a justification. 
56  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 133.
57  Reyna, “Ethical and Practical Issues in Designing and Conducting Clinical Trials in Palliative Care,” 31.
58  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 134.
59  Agar, et. al., “Informed Consent in Palliative Care Clinical Trials: Challenging but Possible,” 485.
60  Illhardt and ten Have, “Research Ethics in Palliative Care,” 207.
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Risk-Benefit Analysis is Difficult to Assess
Estimation of the anticipated risks and benefits is critical in the evaluation of any 
research project, but it is also one of the least developed areas in research ethics.61 
This issue may be more clearly unique to palliative care research.62 To be sure, 
clearly articulating expected risks and benefits in palliative care research poses 
specific challenges.63 Indeed, the NBAC has affirmed that properly assessing risk 
versus benefit is difficult in research studies.64 One issue with risk-benefit analysis in 
palliative care research is the distinction between therapeutic and non-therapeutic 
medical research. This distinction was made in order to differentiate the scope, the 
participants involved, and the context in each of the two categories. In therapeutic 
research, the goal is to treat an individual’s illness with the hopes he/she will recover. 
The context is usually in the hospital, utilizing the hospital’s equipment and the 
experience of the research team. Non-therapeutic research involves the use of healthy 
subjects and seeks to obtain basic scientific data. This is often done for financial 
compensation and the context is the research site, such as a laboratory.65 Thus, 
therapeutic research is designed with the intention of yielding benefit to participants, 
while non-therapeutic research seeks to derive knowledge without direct benefit to 
participants. This distinction can be useful in the ethical assessment of an acceptable 
balance for research participants, between the benefits and the risks of research.66 
Further, it has been recognized that when the distinction between therapeutic and 
non-therapeutic research with respect to the irreversibly ill patient disappears, the 
principle of beneficence may be in danger. Thus, we must ask whether palliative care 
patients can ethically be involved in non-therapeutic research trials.67 
Moreover, another reason that the risks and benefits of palliative care research are often 
hard to assess comprehensively is due to limited preexisting evidence. The frequent 
heterogeneity of study populations has also been perceived as making the weighing of 
61  M. Agrawal, “Voluntariness in Clinical Research at the End of Life,” Journal of Pain and Symptom Management 
25 (2003), S25–S32. 
62  Robert S. Krouse, Alexandra M. Easson, and Peter Angelos, “Ethical Considerations and Barriers to Research 
in Surgical Palliative Care,” Journal of the American College of Surgeons 196, no. 3 (March 2003), 470.
63  M. Masso, Ethical Research in Palliative Care: A Guide Through the Human Research Ethics Committee Process, 
(Canberra: National Palliative Care Program, 2004), 18.
64  National Bioethics Advisory Committee, “The Assessment of Risk and Potential Benefit,” in Research Involving 
Persons with Mental Disorders That May Affect Decisionmaking Capacity,” 1998, https://bioethicsarchive.
georgetown.edu/nbac/capacity/Assessment.htm
65  Illhardt and ten Have, “Research Ethics in Palliative Care,” 203.
66 Masso, Ethical Research in Palliative Care: A Guide Through the Human Research Ethics Committee Process, 18-
19.
67  Illhardt and ten Have, “Research Ethics in Palliative Care,” 203.
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risks and benefits difficult.68 To be certain, it is an ethical duty of all investigators to 
maximize research benefits and minimize research risks. This obligation is expressed 
in US federal guidelines as the requirement that risks to subjects are reasonable in 
relation to anticipated benefits and to the anticipated value of knowledge generated 
by the study.69 For example, this requirement is clearly stated in the Department of 
Health and Human Services IRB guidelines.70 Nonetheless, this goal is often difficult 
to achieve, but is crucially important because the balance of risks and potential 
benefits is a main reason why subjects participate in clinical research. When palliative 
care investigators attempt to meet this challenge they may encounter difficulties 
in two issues: defining research risks and benefits, and measuring them against an 
appropriate standard.71 Each of these will be examined in this section.
In the majority of research studies that involve either healthy participants or patients 
with a known and well-defined medical problem, the benefits and risks of research 
are fairly clear. Medical ethicist and physician David Casarett illustrates this by 
providing an example of a clinical trial comparing two forms of treatment for an 
acute myocardial infarction that might offer potential benefits of improved survival 
or improved cardiac function. The risks of such a trial might include bleeding, 
infection, or death. There ought to be general agreement that these are important 
risks and benefits to be balanced, and should be dutifully explained to the patients. 
However, the issue in palliative care research is that the benefits and risks that are 
important to patients near the end of life may be difficult to assess and define 
because an individual’s goals may change as they near death. It has been suggested 
that, broadly defined, these changes can be characterized by a decreased emphasis 
on survival, and an increased push for pain management, symptom relief, retention 
of dignity, and maintaining social relationships and a semblance of control in their 
lives. Thus, it may be likely that patients’ preferences regarding the potential risks and 
benefits of research may change as well.72 
As patients approach the end of life, they may increasingly emphasize qualities 
such as pain management, dignity, social relationships, and control, as noted 
above. For instance, patients close to death may perceive the time spent answering 
questionnaires, surveys, or doing interviews for research as detrimental to the time 
68  Jonathan Koffman and Fliss Murtagh, “Ethics in Palliative Care Research,” in Textbook of Palliative Medicine, 
edited by Eduardo Bruera, Irene Higginson, Charles F. von Gunte, 192- 201 (Boca Raton, FL: Taylor 
and Francis, 2006), 196.
69  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 135.
70  U.S. Department of Health and Human Services, “Institutional Review Board Guidebook. Chapter III, Basic 
IRB Review,” http://www.hhs.gov/ohrp/archive/irb/irb_chapter3.htm
71  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 135.
72  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 135.
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they could spend strengthening social relationships and addressing any “unfinished 
business” with family members, friends, and associates, while the identical protocol 
may not prove so onerous to patients with a curative disease.73 Thus, palliative care 
patients may prefer to spend their time in ways other than research and may even 
be reluctant to impose any additional burdens on family members.74 Additionally, 
a dying patient’s emphasis on control may have important implications for their 
assessment of research risks and benefits. If the patient’s control over medications and 
dosing is very important to them, any loss of control may be viewed as a significant 
risk. Conversely, a trial that gives patients an increased control over “as needed” 
medication dosing may be viewed as beneficial by patients who value control.75 
The second issue is that measuring the risks and benefits in palliative research 
against an appropriate standard may prove especially challenging for IRBs. IRBs, 
per US federal guidelines, are required to measure the risks of research against the 
risks encountered in daily life or during the performance of routine physical or 
psychological examinations or tests.76 Therefore, even if patients clearly understood 
the risks and benefits of research, it is not clear how investigators and ethics 
committees should balance them in determining whether a proposed research 
study offers an ethical balance of risks and benefits. This task may prove difficult in 
palliative care research because it may be either overly permissive or overly restrictive. 
For example, questionnaires or surveys that are time-consuming may cause little 
discomfort and pose a minimal risk in most research settings. However, for patients 
near the end of life who wish to spend quality time with family members rather than 
completing lengthy surveys, such research may become quite burdensome. Further, 
it has been suggested that judging risks to terminally ill patients by the standards of 
risks encountered in daily life may be misleading and unhelpful, because patients 
who are terminally ill face daily risks of death and suffering that are far greater than 
those faced by other research subjects.77 What is more, in a 2015 research survey of 
the delegates at the 7th Pediatric Palliative Care Conference, approximately one-third 
of respondents in the study identified the IRB approval process as a major barrier 
73  Jubb, “Palliative Care Research: Trading Ethics for an Evidence Base,” 344.
74  Blair Henry and Damon C. Scales, “Ethical Challenges in Conducting Research on Dying Patients and Those 
at High Risk of Dying,” Accountability in Research 19, no. 1 (2012): 7.
75  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 135-36.
76  U.S. Department of Health and Human Services, “Institutional Review Board Guidebook. Chapter III, Basic 
IRB Review,” http://www.hhs.gov/ohrp/archive/irb/irb_chapter3.htm
77  Casarett, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 136.
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to palliative care research, citing the approval process as “arcane”, “challenging,” and 
“restrictive”.78 This would be worth examining in further research.  
Response to the Difficulty of Assessing Risk-Benefit Analysis
As stated briefly above, Louise de Raeve has argued that strong moral grounds exist 
for objecting to palliative care research based on a risk-benefit perspective. De Raeve 
asserts that it is not clear from the outset of the study that participants will get 
anything out of the experience, which may be unethical. The author couples this 
argument with describing the “seductiveness” of palliative care research. That is, the 
researcher often provides a nonjudgmental listening ear, interest, and close attention 
to the patient, which is something the patient may not have received in a very long 
time, making a continued relationship with the investigator very enticing.79 However, 
this second issue is not unique to palliative care research and, thus, should not be 
grounds for disqualifying research in that field. Further, it is not altogether clear that 
palliative care patients do not benefit from research. 
At least two benefits of palliative care research to participants have been identified. 
During the course of the research study, investigators may have several opportunities 
to maximize the potential benefits of research to participants. In an interventional 
study, participants may be free to choose their own intervention. While, ideally, a 
new intervention should have a reasonable chance of success, more important may 
be that it offers to participants a significant potential benefit or improvement over 
other interventions that are available to patients outside the study. Further, potential 
benefits of a study can be enhanced by choosing an active control design, rather than 
a placebo. It must be noted that these suggestions ought to be tempered by realizing 
that potential benefits of research are never certain. If they were completely certain, 
equipoise could not be maintained. Nonetheless, investigators generally design trials 
of interventions for which there is at least some evidence of effectiveness. Moreover, 
palliative care studies may also benefit participants by the data gathering that occurs. 
This data collected during a descriptive study may identify inadequately treated 
pain, dissatisfaction with pain management, or related problems such as depression 
or anxiety. Investigators can then use this data to improve the participant’s care. 
Therefore, it does not seem true that palliative care patients cannot benefit at all from 
research studies.80
78  Emma Beecham, Briony F. Hudson, Linda Oostendorp1, Bridget Candy, Louise Jones, Vickey Vickerstaff, 
Monica Lakhanpaul, Paddy Stone, Lizzie Chambers, Doug Hall, Kate Hall, Thines Ganeshamoorthy, Margaret 
Comac, and Myra Bluebond-Langner, “A call for increased paediatric palliative care research: Identifying barriers,” 
Palliative Medicine 30, no. 10 (2016): 979-80.
79  de Raeve, “Ethical Issues in Palliative Care Research,” 303.
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Therefore, as has been identified in the above section, the weighing of risks and 
benefits in palliative care settings may present distinct ethical considerations that 
merit special attention. This judgment seems correct, especially when we consider 
that the risks and benefits that are important to patients near the end of life may 
be much more difficult to define because their goals may change significantly as 
they near death. Further, as has been explained above, it can be difficult to measure 
risks and benefits against the risks of everyday life because palliative care patients 
are in a unique phase of life. However, it should not be concluded that these 
challenges are insurmountable.81 Robert Krouse, Ira Byock, and others have echoed 
this sentiment by affirming that barriers in palliative care research can be overcome 
with well-constructed studies carried out by thoughtful research teams. Indeed, the 
methodological difficulties in palliative care research are all surmountable through 
existing techniques and appropriately careful scientific design.82
In order to demonstrate that these concerns are surmountable, at least two strategies 
are essential to this endeavor. First, in order to define and weigh risks and benefits 
properly, data that describe how patients perceive the risks and benefits of research 
are necessary.83 If palliative care researchers hope to find a balance between risks and 
benefits that participants will find acceptable then these data are essential. Researchers 
should also try to consider these risks and benefits in relation to those that patients 
near the end of life typically experience in their daily routines. A second strategy is 
that when IRBs review the protocols for palliative care research studies examining the 
physical aspects of palliative care, they will be better prepared to assess and weigh the 
risks and benefits of research if they include at least one healthcare professional with 
expertise in the field of palliative care. Indeed, IRB reviews have been considered to 
be a significant impediment to conducting quality research in palliative care because 
they are often ill-equipped to handle such protocols and, thus, promote a natural 
protectiveness towards what is perceived to be a vulnerable population.84 Involving 
a healthcare professional with expertise in this area might curtail this. The Common 
Rule recommends that this be done for other vulnerable populations such as children. 
The IRB guidelines of the NIH extend this suggestion to palliative care research as 
81  Jubb, “Palliative Care Research: Trading Ethics for an Evidence Base,” 344.
82  Robert Krouse, Kenneth E. Rosenfeld, Marcia Grant, Noreen Aziz, Ira Byock, Jeffrey Sloan, and David 
Casarett, “Palliative Care Research: Issues and Opportunities,” Cancer Epidemiology, Biomarkers & Prevention, 13, 
no. 3 (March 2004): 337-39.  
83  J.H.T. Karlawish, “Permissible Risk and Acceptable Benefit (The Ethics of Research Involving the Cognitively 
Impaired),” Forum 7 (1997): 277–285.
84  P.W. Keeley, “Improving the Evidence Base in Palliative Medicine: A Moral Imperative,” Journal of Medical 
Ethics 34, no. 10 (2008), 758.
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well. Thus, this person may be very helpful in focusing the IRB on the risks and 
benefits that are likely to be most important to patients in their stage of life.85 
In summary, palliative care research does seem to be unique because the evaluation 
and parameters of the risk benefit analysis, as well as the burden of the research upon 
the patient, may change significantly as patients near death. What is sure is that 
physicians and caregivers have the moral duty to support research, but in each case 
this must be done on the basis of a concrete risk-benefit analysis. The greater the 
risks are predicted to be, the greater the concrete benefits for the involved participant 
should be. Hence, studies that are likely to provide small benefit can only be justified 
if they bear low risk. While these concerns may be difficult to manage, the majority 
of literature appears to conclude that they are surmountable because of medicine’s 
commitment to regarding irreversibly ill patients as autonomous and capable of 
freely consenting to research participation.86 
Further Considerations to Protect Research Subjects
As has been presented in this analysis, there does not appear to be a compelling case 
for believing that research in palliative care is significantly more distinct than research 
in other fields as to require distinct ethical guidelines. Thus, patients suffering from 
an irreversible disease can be involved in medical research because the principles of 
research ethics seem to be appropriate for their protection.87 However, this does not 
mean that there are no serious ethical concerns that need to be taken into consideration. 
This section will consider how further to safeguard palliative care patients who are 
involved in research and mitigate ethical concerns. The first subsection will consider 
specific suggestions to enhance ethical conduct and protect patients, and the second 
will look at the notion of compassion and vigilance as strategies to manage ethical 
concerns in palliative care research.
Specific Suggestions to Enhance Ethical Conduct  
Franz-Josef Illhardt has recognized that, commonly, pharmaceutical companies will 
enroll critically ill patients into clinical trials if they meet the following criteria: 1) a 
life expectancy of more than three months, 2) informed consent for the trial, and 3) 
no other concomitant life-threatening diseases. As has been reported, these criteria 
have been applied frequently to studies in the second-line treatment of cancer. 
85  Casarett and Karlawish, “Are Special Ethical Guidelines Needed for Palliative Care Research?” 136.
86  Illhardt and ten Have, “Research Ethics in Palliative Care,” 209-10.
87  Illhardt and ten Have, “Research Ethics in Palliative Care,” 207.
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However, there are many items to consider, for we must question whether these 
guidelines are sufficient to protect vulnerable persons such as the incurably ill.88 
When analyzing the first criterion regarding the life expectancy, problems may arise 
as we recognize that patients who come close to the threshold of three months of life 
expectancy should be protected against any kind of exploitation. This is true both 
in the research context and out of it. Indeed, caregivers have the moral and legal 
obligation to safeguard the interests of the patients. As death draws near, patients 
require the devotion and support of their families and other professionals to help 
them in coping with their fate. We must question whether they also need the progress 
of science from which they may never receive benefits.89  
The second criterion also poses problems. Physicians have reported that many 
terminally ill patients agree to participate in research trials simply out of a sense 
of altruism. However, an altruistic attitude can be a sign of moral pressure when 
patients in the last stages of life opt for this moral mechanism. Patients may believe 
that they are burdens to their family and caregivers, and that they can enhance the 
value of their lives by participating in research. To be certain, this is not a mark of 
moral freedom. It is the duty of the caregiver to make the differentiation between a 
free altruistic attitude and the fear of not being free disguised as altruism.90 
The final criterion that has been presented was an absence of concomitant life-
threatening diseases. This is also often problematic. While only having the disease 
that is the prerequisite of the research aids the investigator in gaining control over 
the project, those patients who are incurably ill typically have multiple diseases and 
affected organs. It has been recognized that, due to this, research with patients in 
palliative care facilities can easily create situations in which the endpoints of research 
put risks upon the patient’s process of treatment or bring about more inconveniences 
to the patient than the caregivers can ethically accept.91  
There are a variety of ways to enhance the ethical conduct of palliative care research. 
This section will discuss specific suggestions in regards to how patients are enrolled, 
how the study is designed, and how it is conducted. In regards to patient enrollment, 
potential palliative care research participants ought to be advised to discuss their 
participation in a research trial with family members or other close friends. As has 
been briefly mentioned, palliative care stresses the importance of families and that 
they represent the fundamental unit of care. Because of this, the patient’s family 
88  Illhardt and ten Have, “Research Ethics in Palliative Care,” 207-08.
89  Illhardt and ten Have, “Research Ethics in Palliative Care,” 208.
90  Illhardt and ten Have, “Research Ethics in Palliative Care,” 208.
91  Illhardt and ten Have, “Research Ethics in Palliative Care,” 208.
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or close friends should be involved in discussions on the decision to participate in 
research trials to the degree the patient will allow. It is also not uncommon that 
the family members will share research burdens due to the transport needs of the 
patient, medication arrangements, and other qualities of the study. It is reasonable 
for the family members or close friends who share these burdens to have their input 
recognized and honored as well. Further, as has been held throughout this analysis, 
there does not seem to be a valid reason to exclude potential research participants on 
the basis of age, frailty, or mental or physical disability. Members of society should 
not be unfairly excluded from the potential benefits of research participation. It is 
not ethically acceptable to stigmatize or stereotype an individual’s rights because of 
a perceived attribute.92
The design of the clinical trial should also be formulated in such a way as to maximize 
ethical conduct. Research protocols should be written in such a manner as to encourage 
understanding and participation by members of the palliative care team who work 
with the research participant. This is grounded in the basic principle of palliative 
care as a multidisciplinary activity. Further, the trial methodology must emphasize 
the maintenance of patient comfort and dignity through the routine inclusion of 
assessments of the factors which contribute to this goal. Certainly, the recognition 
and alleviation of suffering is the primary reason for palliative care. Clinical trials 
that reflect this goal must be designed. Practical expressions of this concept include 
routine use of symptom control and quality of life assessments.93  
During the conduct of clinical trials, particularly in studies that involve greater-than-
minimal risk, it is recommended that tests of cognitive status be repeated at regular 
intervals. Palliative care patients may become incompetent subsequent to enrollment 
in a research trial and their continued participation should be dependent upon a 
surrogate’s consent and the demonstration of continued patient benefit while on the 
experimental therapy, as well as the evidence that the therapy is not the cause of their 
development of incompetence. Conversely, if an incompetent patient should gain 
competency during a study, they should only continue in the study upon directly 
attaining their informed consent.94   
Compassion and Vigilance as Strategies to Manage Ethical Concerns 
In a recent empirical study, investigators found that when clinical researchers and 
their protocols reflected an environment of both compassion and vigilance, ethical 
concerns can be managed. In the study, the concept of compassion was reflected 
92  MacDonald and Weijer, “Ethical Issues in Palliative Care Research,” 82.
93  MacDonald and Weijer, “Ethical Issues in Palliative Care Research,” 82.
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in strategies that represented heightened sensitivity to the needs of the research 
participants, such as allowing extra time to solicit consent, gently building up to 
sensitive questions, developing backup protocols, careful attention to the use of 
language, and methodological flexibility. Further, compassion was coupled with 
exercising heightened vigilance during every step of the research process about the 
possible effects of study participation on the participants’ emotional and physical 
well-being, ensuring the research did not interfere with clinical care.95
Compassion has been recognized by numerous commentators to be a great virtue, 
if not a duty, of all physicians.96 This easily transfers to the clinical trial investigator. 
The compassionate behavior of a physician or investigator is not only desired because 
it is nice for the patient; it is taken as a sign of an authentic attitude that underlies 
the fiduciary relationship between physician and patient.97 When one examines 
the definition of compassion, we see how important this is to ethical palliative care 
research. The relevant literature on the etymology and meaning of the word provides 
slightly nuanced conclusions. The etymology of the two Latin roots suggests that the 
term means the ability to share or to enter into another’s experience of suffering.98 
While it has been described as the participation in the suffering of others, it can 
also be thought of as something spontaneous and benevolent.99 Working with this 
definition in mind, it seems desirable to have compassionate healthcare professionals 
who sense that compassion is one of their professional virtues.
To be a concerned, compassionate physician or investigator means to be involved, 
and to say that compassion is a physician’s duty, a point that will be elaborated below, 
is to assert an obligation to employ some of humankind’s natural ability to feel with 
the sufferings of others.100 The obligation to relieve human suffering is virtually 
synonymous with the practice of medicine, and the suffering of the patient and the 
compassion of the physician are intimately related. Eric Cassell has asserted that 
there are three goals which would, if met by the actions of physicians, promise better 
care and result in lessened suffering for patients. The first goal is that all diagnostic 
or therapeutic plans be made in terms of the sick, suffering person, not the disease. 
The second goal is to maximize the functions of the patient, their quality of life, not 
95  Hickman, et. al., “Compassion and Vigilance: Investigators’ Strategies To Manage Ethical Concerns in 
Palliative and End-of-Life Research,” 888.
96  C.J. Dougherty, and R. Purtilo, “Physicians’ Duty of Compassion,” Cambridge Quarterly of Healthcare Ethics 
4, no. 4 (Fall 1995): 426.
97  P. Gelhaus, “The Desired Moral Attitude of the Physician: (II) Compassion,” Med Health Care Philos 15, no. 
4 (Nov 2012): 403.
98  Dougherty and Purtilo, “Physicians’ Duty of Compassion,” 427.
99  Gelhaus, “The Desired Moral Attitude of the Physician: (II) Compassion,” 401.
100  Eric J. Cassell, The Nature of Suffering and the Goals of Medicine. 2nd ed. (New York: Oxford University 
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length of life. The third goal is to minimize both the patient’s and family’s suffering. 
As Cassell affirms, these aims are interlocking in that they arise from the more basic 
idea that physicians and other healthcare professionals should focus primarily on the 
best interests of the patient rather than treatment of the disease.101
The physician’s duty to provide due care requires them to maintain a judicious 
range of professional skills and use them with appropriate diligence. Due care bars 
the deliberate or negligent imposition of unreasonable risks on patients. Although 
compassion provides no guarantees in this arena, compassion certainly makes it more 
likely that a healthcare provider will act with due care as changing circumstances 
require. Indirect evidence for this claim can be found in the legal arena where lawsuits 
for malpractice, which is the alleged violation of a standard of due care, often seem 
more closely linked to failed relationships with patients than to inadequate technical 
skills.102
While there are exceptions to nearly every rule, generally speaking, a physician’s or 
investigator’s duties are more readily satisfied when they bring a sense of compassion 
to their encounters with patients and research subjects. To contrast this, the physician 
or investigator who lacks compassion is more likely to be unaware of a patient’s 
interest and less motivated to place it first in situations of conflict. Due care that is 
void of compassion is subject to compromise in various scenarios in which standards 
are implicit and unenforceable, and the uncompassionate physician or investigator 
is less likely to appreciate and protect patient’s vulnerability. It can be assessed that 
the connection of compassion to the satisfaction of the core duties of physicians and 
investigators is so close as to make compassion itself a duty.103 Indeed, principles 
of medical ethics are sterile if not applied within a compassionate environment 
by wise, charitable, and moral investigators.104 Therefore, provided investigators 
compassionately apply ethical principles to their work, there is no justification for 
not endeavoring to improve the quality of palliative care through research.105 
Conclusion 
This analysis has examined the question of whether the distinctiveness of palliative 
care research requires distinct ethical guidelines. The analysis first provided an 
101  Eric J. Cassell, The Nature of Suffering and the Goals of Medicine. 2nd ed. (New York: Oxford University 
Press, 2004), 282.
102  Dougherty and Purtilo, “Physicians’ Duty of Compassion,” 429.
103  Dougherty and Purtilo, “Physicians’ Duty of Compassion,” 429.
104  MacDonald and Weijer, “Ethical Issues in Palliative Care Research,” 80.
105  Jubb, “Palliative Care Research: Trading Ethics for an Evidence Base,” 345.
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overview on the history of the research process. Then, three arguments were 
presented that have been used to support the conclusion that palliative care does in 
fact raise distinct ethical questions that may merit distinct ethical guidelines. The 
issues of vulnerability and informed consent were examined in detail, and it was 
determined that though these topics are serious, the principles of research ethics are 
sufficient to protect participants. Section 4 examined the issue of risk-benefit analysis 
and discussed the difficulties of this assessment. It was concluded that risk-benefit 
analysis in palliative care research might be distinct from other fields of research. 
However, these issues appear to be surmountable. Lastly, section 5 examined further 
considerations to protect research subjects, including the notions of compassion and 
vigilance. 
To be certain, research is essential to improve medical care and increase our knowledge 
base. Dying patients or those at high risk of dying should not be denied the valuable 
opportunity to participate in such research. However, such research should always 
adhere to accepted ethical principles. Research must respect the dignity of patients, 
it must be scientifically valid, it should have the potential to benefit the targeted 
population, and it should minimize any potential for harm. Research involving 
patients that are at the end of life should be designed considering their emotional, 
social, physical, and spiritual taxing situations. Particularly, provisions should be 
taken to ensure that informed consent is obtained from patients who are capable, 
free from coercion, and not harboring false expectations about the likelihood of 
benefiting from the study intervention. Adhering to these principles will help ensure 
that patients can ethically participate in research that has the potential to advance 
knowledge and improve future patient care. 
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Zahtijeva li profiliranost istraživanja 
o palijativnoj skrbi različite etičke 
smjernice?
SAŽETAK
Palijativna skrb i skrb na kraju života doživljava promjene, postaje sve rasprostranjenija i 
poboljšava se za pacijente. Ipak, trenutno dostupna literatura iz tog područja navodi da 
su materijali o palijativnoj skrbi i skrbi na kraju života donekle ograničeni. Istraživanja o 
odlukama o liječenju, obiteljskoj skrbi i naputku za buduću zdravstvenu njegu u određenim 
okolnostima samo su neka od područja koja zahtijevaju velike istraživačke napore. Istraživanje 
o palijativnoj skrbi bitno je zbog stalnog pružanja učinkovitih tretmana onima koji pate u 
posljednjim fazama terminalne bolesti. Doista, cilj dobrog istraživanja palijativne skrbi 
ublažavanje je patnje i poboljšanje kvalitete života. Slično kao i u bilo kojem drugom području, 
programi palijativne skrbi moraju se razvijati na istraživačkoj osnovi, a njega pacijenata će 
patiti ako nije potpomognuta znanstvenim istraživanjem. No, oni koji su protiv ove potrebe 
su oni koji ostaju pri mišljenju da su etički i praktični izazovi istraživanja palijativne skrbi 
jedinstveni i nepremostivi. Ova analiza razmatra jesu li različite etičke smjernice potrebne za 
istraživanje palijativne skrbi.
Ključne riječi: palijativna skrb; palijativna sedacija; ranjivost; skrb na kraju života; analiza 
rizika i koristi; sposobnost odlučivanja.
